Transcriptomal and Molecular Characterization of Tumor Associated Monocytes/Macrophages in Human Cancers

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by National University Hospital, Singapore
Information provided by (Responsible Party):
Haematology-Oncology, National University Hospital, Singapore Identifier:
First received: September 15, 2009
Last updated: January 8, 2014
Last verified: January 2014
Recent studies from both human and mice cancer models have demonstrated a crucial role for monocytes/macrophages in contributing to cancer progression and disease prognosis. However, since each cancer subtypes is associated with a unique tumor microenvironment in terms of its anatomical location, cytokine/chemokine profiles and stromal components, the functional contribution of tumor infiltrating cells such as the monocytes/macrophages can be equally diverse, depending on the type of cancer. Therefore to obtain a global understanding of the role of host immune cells in cancer progression, it is necessary to accurately characterize these cells in the context of the tumor microenvironment for several cancer subtypes rather than a single cancer. In view of this, this pilot proposal aims to carryout a systems approach in characterizing the functional phenotype of monocyte/macrophage lineage in 4 diverse human cancer types [e.g., Colorectal Cancer, Nasopharyngeal carcinoma, Hepatocellular (liver) cancer and Renal cell carcinoma (kidney cancer)] and the molecular basis of tumor-induced immunosuppression in each of these conditions. Besides providing a global view of the host innate immunity and its molecular basis in these human cancer, the outcome of this investigation will be crucial in defining the scopes of specific immunotherapy strategies to overcome tumor-induced immunosuppression and induce monocyte/macrophage-mediated antitumor response.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Transcriptomal and Molecular Characterization of Tumor Associated Monocytes / Macrophages in Human Cancers

Further study details as provided by National University Hospital, Singapore:


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Sampling Method:   Probability Sample
Study Population
15 subjects from each tumor type. (NUH: NPC 15, CRC 15, RCC 7, HCC 8. AH: HCC 7,TTSH: RCC 8)

Inclusion Criteria:

Subjects must meet all of the inclusion criteria to participate in this study:

  • Diagnosed NPC, RCC, HCC or colorectal cancer patients. (Preoperative histologic diagnosis is not required for RCC and HCC.)
  • All stages of disease are eligible.
  • Adult patients above 21.
  • Ability to provide informed consent.

Exclusion Criteria:

Subjects meeting any of the exclusion criteria at baseline will be excluded:

  • Active infection.
  • Immunocompromised or other active immune disorders.
  • Have received chemotherapy or other immunomodulating therapy in the past 6 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00979277

Contact: Alvin Wong, MBBS, MRCP 65 6772 2527

National University Hospital Recruiting
Singapore, Singapore, 119074
Contact: Alvin Wong, MBBS, MRCP    65 6772 2527   
Principal Investigator: Alvin Wong, MBBS, MRCP         
Sponsors and Collaborators
National University Hospital, Singapore
  More Information

Responsible Party: Haematology-Oncology, Alvin Wong, Senior Consultant, National University Hospital, Singapore Identifier: NCT00979277     History of Changes
Other Study ID Numbers: MC03/17/07
Study First Received: September 15, 2009
Last Updated: January 8, 2014
Health Authority: Singapore: Domain Specific Review Boards processed this record on November 30, 2015